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To the Editor: We appreciated the attentive and interesting 
paper by Huai et al.[1] on the protective effects of pravastatin on 
preeclampsia (PE)‑like effects in mouse models. We would like to 
remind that PE is the first cause of illness and death for pregnant 
women and their children worldwide, the highest prevalence being 
in South America. Hence, every measure capable of preventing 
or averting the full‑blown eclampsia is very welcomed. In mice, 
Helicobacter pylori infection exerted a negative effect upon 
pregnancy; in humans, Eslick et al.[2] observed fetal intrauterine 
growth restrictions in newborns from mothers infected with 
H. pylori. This bacterium was also shown to be an independent risk 
factor for cerebral ischemia of atherothrombotic origin. Therefore, 
we reasoned that the cerebral ischemia typically occurring in PE 
could be associated with the infection by this pathogen. Indeed, 
we and others found it to be the case;[3] in Turin, Italy, 90.6% 
of fetal intrauterine growth restrictions occurred in newborns 
from PE mothers carrying pathogenic strains of H. pylori with 
an odd ratio of 54.97 (95% confidence interval: 9.24–326.88), 
compared to noncytotoxin‑associated gene A (cagA) strain‑infected 
mothers.[4] These strains are characterized by the presence of the 
cagA coding for the CagA protein that is endowed with an increased 
inflammatory potential. For example, the infection in mouse by 
CagA‑expressing strains induces a Th1‑type response even at the 
level of the endometrium. Such phenomenon would downregulate 
the secretion of cytokines produced by Th2 immunocytes, which 
enable fetal survival. Not surprisingly, South American countries 
have a very high prevalence of both PE and H. pylori infection, 
whose long‑term consequence, i.e., gastric cancer, still is the first 
cause of cancer death in Peru and Colombia, the second in Mexico 
and Brazil, as well as in Japan. Referring to possible causes of 
ischemia, H. pylori was shown to bind von Willebrand factor and 
to interact with glycoprotein Ib to induce platelet aggregation;[5] not 
only, but both in mice and in humans, H. pylori infection causes 
platelets activation and that of endothelial cells. All of the above is 
present in the preeclamptic state that could eventually lead to the 
full‑blown eclampsia. We believe that it would be prudent to add 
H. pylori in the workup of pregnancy tests.
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